Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release

References

• Flegal KM Kruszon-Moran D Carroll MD Fryar CD Ogden CL Trends in obesity among adults in the United States, 2005 to 2014 J Am Med Assoc 2016 315 21 2284 2291
   PubMed Web of Science ®Google Scholar
• Ng M Fleming T Robinson M Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet 2014 384 9945 766 781 24880830
   PubMed Web of Science ®Google Scholar
• Calle EE Rodriguez C Walker-Thurmond K Thun MJ Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 2003 348 17 1625 1638 12711737
   PubMed Web of Science ®Google Scholar
• Hurt RT Frazier TH McClave SA Kaplan LM Obesity epidemic: overview, pathophysiology, and the intensive care unit conundrum J Parenter Enteral Nutr 2011 35 5 Suppl 4S 13S
   Google Scholar
• Hurt RT Kulisek C Buchanan LA McClave SA The obesity epidemic: challenges, health initiatives, and implications for gastroenterologists Gastroenterol Hepatol (N Y) 2010 6 12 780 792 21301632
   PubMedGoogle Scholar
• Flegal KM Kit BK Orpana H Graubard BI Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis J Am Med Assoc 2013 309 1 71 82
   PubMed Web of Science ®Google Scholar
• Finkelstein EA Trogdon JG Cohen JW Dietz W Annual medical spending attributable to obesity: payer-and service-specific estimates Health Aff (Millwood) 2009 28 5 w822 w831 19635784
   PubMed Web of Science ®Google Scholar
• Trogdon JG Finkelstein EA Hylands T Dellea PS Kamal-Bahl SJ Indirect costs of obesity: a review of the current literature Obes Rev 2008 9 5 489 500 18331420
   PubMed Web of Science ®Google Scholar
• Allison DB Zannolli R Narayan KM The direct health care costs of obesity in the United States Am J Public Health 1999 89 8 1194 1199 10432905
   PubMed Web of Science ®Google Scholar
• Shah M Hurt RT Mundi MS Phenotypes of obesity: how it impacts management. Curr Gastroenterol Rep 2017 19 11 55 28948512
   PubMedGoogle Scholar
• Burrell RA McGranahan N Bartek J Swanton C The causes and consequences of genetic heterogeneity in cancer evolution Nature 2013 501 7467 338 345 24048066
   PubMed Web of Science ®Google Scholar
• Hurt RT Edakkanambeth Varayil J Ebbert JO New pharmacological treatments for the management of obesity. Curr Gastroenterol Rep 2014 16 6 394 24828101
   PubMedGoogle Scholar
• Hurt RT Frazier TH Mundi MS Novel nonsurgical endoscopic approaches for the treatment of obesity Nutr Clin Pract 2017 32 4 493 501 28622478
   PubMed Web of Science ®Google Scholar
• Wing RR Bolin P Brancati FL Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes N Engl J Med 2013 369 2 145 154 23796131
   PubMed Web of Science ®Google Scholar
• Knowler WC Fowler SE Hamman RF 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study Lancet 2009 374 9702 1677 1686 19878986
   PubMed Web of Science ®Google Scholar
• Patel DK Stanford FC Safety and tolerability of new-generation anti-obesity medications: a narrative review Postgrad Med 2018 130 2 1 10
   Web of Science ®Google Scholar
• Belviq® (lorcaserin) extended release tablets [prescribing information] Tokyo Eisai, Inc 2017
   Google Scholar
• Drug Enforcement Administration Schedules of controlled substances: placement of lorcaserin into Schedule IV. Federal Register The Daily Journal of the United States Government 2013 78 89
   Google Scholar
• Evans EA Sullivan MA Abuse and misuse of antidepressants. Subst Abuse Rehabil 2014 5 107 120 25187753
   PubMedGoogle Scholar
• Voigt JP Fink H Serotonin controlling feeding and satiety. Behav Brain Res 2015 277 14 31 25217810
   PubMed Web of Science ®Google Scholar
• Roth BL Drugs and valvular heart disease N Engl J Med 2007 356 1 6 9 17202450
   PubMed Web of Science ®Google Scholar
• Connolly HM Crary JL McGoon MD Valvular heart disease associated with fenfluramine-phentermine N Engl J Med 1997 337 9 581 588 9271479
   PubMed Web of Science ®Google Scholar
• Thomsen WJ Grottick AJ Menzaghi F Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization J Pharmacol Exp Ther 2008 325 2 577 587 18252809
   PubMed Web of Science ®Google Scholar
• Smith BM Smith JM Tsai JH Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity J Med Chem 2008 51 2 305 313 18095642
   PubMed Web of Science ®Google Scholar
• Smith BM Smith JM Tsai JH Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity Bioorg Med Chem Lett 2005 15 5 1467 1470 15713408
   PubMed Web of Science ®Google Scholar
• Weissman NJ Sanchez M Koch GG Smith SR Shanahan WR Anderson CM Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials Circ Cardiovasc Imaging 2013 6 4 560 567 23661689
   PubMed Web of Science ®Google Scholar
• Farr OM Upadhyay J Gavrieli A Lorcaserin administration decreases activation of brain centers in response to food cues and these emotion- and salience-related changes correlate with weight loss effects: a 4-week-long randomized, placebo-controlled, double-blind clinical trial Diabetes 2016 65 10 2943 2953 27385157
   PubMed Web of Science ®Google Scholar
• Volkow ND Fowler JS Wang GJ The addicted human brain: insights from imaging studies J Clin Invest 2003 111 10 1444 1451 12750391
   PubMed Web of Science ®Google Scholar
• Usmani KA Chen WG Sadeque AJ Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist Drug Metab Dispos 2012 40 4 761 771 22266842
   PubMed Web of Science ®Google Scholar
• Christopher R Morgan M Ferry J Single- and multiple-dose pharmacokinetics of a lorcaserin extended-release tablet Clin Ther 2016 38 10 2227 2238 e2224 27692638
   PubMed Web of Science ®Google Scholar
• Boyer EW Shannon M The serotonin syndrome N Engl J Med 2005 352 11 1112 1120 15784664
   PubMed Web of Science ®Google Scholar
• Mackay FJ Dunn NR Mann RD Antidepressants and the serotonin syndrome in general practice Br J Gen Pract 1999 49 448 871 874 10818650
   PubMed Web of Science ®Google Scholar
• Nguyen CT Zhou S Shanahan W Fain R Lorcaserin in obese and overweight patients taking prohibited serotonergic agents: a retrospective analysis Clin Ther 2016 38 6 1498 1509 27206567
   PubMed Web of Science ®Google Scholar
• Milatovich A Hsieh CL Bonaminio G Tecott L Julius D Francke U Serotonin receptor 1c gene assigned to X chromosome in human (band q24) and mouse (bands D-F4) Hum Mol Genet 1992 1 9 681 684 1302605
   PubMedGoogle Scholar
• Tecott LH Sun LM Akana SF Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors Nature 1995 374 6522 542 546 7700379
   PubMed Web of Science ®Google Scholar
• Yuan X Yamada K Ishiyama-Shigemoto S Koyama W Nonaka K Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes Diab Tologia 2000 43 3 373 376
   Web of Science ®Google Scholar
• Godlewska BR Olajossy-Hilkesberger L Ciwoniuk M Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene Pharmacogenomics J 2009 9 4 234 241 19434072
   PubMed Web of Science ®Google Scholar
• Ma X Maimaitirexiati T Zhang R HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis Int J Psychiatry Clin Pract 2014 18 4 229 242 25152019
   PubMed Web of Science ®Google Scholar
• Malan-Muller S Kilian S van den Heuvel LL A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia Schizophr Res 2016 170 1 1 17 26621002
   PubMed Web of Science ®Google Scholar
• De Luca V Mueller DJ de Bartolomeis A Kennedy JL Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis Int J Neuropsychopharmacol 2007 10 5 697 704 17291373
   PubMed Web of Science ®Google Scholar
• Sicard MN Zai CC Tiwari AK Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis Pharmacogenomics 2010 11 11 1561 1571 21121776
   PubMed Web of Science ®Google Scholar
• Fidler MC Sanchez M Raether B A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial J Clin Endocrinol Metab 2011 96 10 3067 3077 21795446
   PubMed Web of Science ®Google Scholar
• O’Neil PM Smith SR Weissman NJ Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study Obesity (Silver Spring) 2012 20 7 1426 1436 22421927
   PubMed Web of Science ®Google Scholar
• Smith SR Weissman NJ Anderson CM Multicenter, placebo-controlled trial of lorcaserin for weight management N Engl J Med 2010 363 3 245 256 20647200
   PubMed Web of Science ®Google Scholar
• Eberhardt MS Ogden CL Engelgau M Cadwell B Hedley AA Saydah S Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988–1994 and 1999–2002 Morb Mortal Wkly Rep 2004 53 45 1066 1068
   Google Scholar
• Neff LM Broder MS Beenhouwer D Chang E Papoyan E Wang ZW Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity Clin Obes 2017 7 6 337 346 28891142
   PubMed Web of Science ®Google Scholar
• Levin ED Johnson JE Slade S Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats J Pharmacol Exp Ther 2011 338 3 890 896 21636655
   PubMed Web of Science ®Google Scholar
• Zeeb FD Higgins GA Fletcher PJ The serotonin 2C Receptor agonist lorcaserin attenuates intracranial self-stimulation and blocks the reward-enhancing effects of nicotine ACS Chem Neurosci 2015 6 7 1231 1240 25781911
   PubMed Web of Science ®Google Scholar
• Gannon BM Sulima A Rice KC Collins GT Inhibition of cocaine and 3,4-Methylenedioxypyrovalerone (MDPV) self-administration by lorcaserin is mediated by 5-HT2C receptors in rats J Pharmacol Exp Ther 2018 364 2 359 366 29217539
   PubMedGoogle Scholar
• Collins GT Gerak LR Javors MA France CP Lorcaserin reduces the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys J Pharmacol Exp Ther 2016 356 1 85 95 26534942
   PubMed Web of Science ®Google Scholar
• Rezvani AH Cauley MC Levin ED Lorcaserin, a selective 5-HT(2C) receptor agonist, decreases alcohol intake in female alcohol preferring rats. Pharmacol Biochem Behav 2014 125 8 14 25109272
   PubMed Web of Science ®Google Scholar
• Shanahan WR Rose JE Glicklich A Stubbe S Sanchez-Kam M Lorcaserin for smoking cessation and associated weight gain: a randomized 12-week clinical trial Nicotine Tob Res 2017 19 8 944 951 27815511
   PubMed Web of Science ®Google Scholar
• Jorenby DE Hays JT Rigotti NA Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial J Am Med Assoc 2006 296 1 56 63
   PubMed Web of Science ®Google Scholar
• Pisinger C Jorgensen T Waist circumference and weight following smoking cessation in a general population: the Inter99 study Prev Med 2007 44 4 290 295 17222450
   PubMed Web of Science ®Google Scholar
• Aubin HJ Farley A Lycett D Lahmek P Aveyard P Weight gain in smokers after quitting cigarettes: meta-analysis Br Med J 2012 345 e4439 22782848
   PubMed Web of Science ®Google Scholar
• Williamson DF Madans J Anda RF Kleinman JC Giovino GA Byers T Smoking cessation and severity of weight gain in a national cohort N Engl J Med 1991 324 11 739 745 1997840
   PubMed Web of Science ®Google Scholar
• Farley AC Hajek P Lycett D Aveyard P Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2012 1 CD006219 22258966
   PubMed Web of Science ®Google Scholar
• Hurt RT Croghan IT Schroeder DR Hays JT Choi DS Ebbert JO Combination varenicline and lorcaserin for tobacco dependence treatment and weight gain prevention in overweight and obese smokers: a pilot study Nicotine Tob Res 2017 19 8 994 998 27852796
   PubMed Web of Science ®Google Scholar
• Saini SD Schoenfeld P Kaulback K Dubinsky MC Effect of medication dosing frequency on adherence in chronic diseases Am J Manag Care 2009 15 6 e22 e33 19514806
   PubMed Web of Science ®Google Scholar
• Claxton AJ Cramer J Pierce C A systematic review of the associations between dose regimens and medication compliance Clin Ther 2001 23 8 1296 1310 11558866
   PubMed Web of Science ®Google Scholar
• Hanson KA Payne KA Targeted literature review of medication event monitoring systems to evaluate adherence in observational real-world studies. Value Health 2014 17 7 A645
   Web of Science ®Google Scholar